Edition:
India

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

59.79USD
2:29am IST
Change (% chg)

$0.50 (+0.84%)
Prev Close
$59.29
Open
$58.70
Day's High
$59.86
Day's Low
$58.63
Volume
320,821
Avg. Vol
366,009
52-wk High
$73.98
52-wk Low
$45.31

Chart for

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 2.38
Market Cap(Mil.): $8,225.50
Shares Outstanding(Mil.): 143.03
Dividend: --
Yield (%): --

Financials

BRIEF-SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)

* SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF)

09 Nov 2017

BRIEF-Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin

* Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer

08 Nov 2017

BRIEF-Seattle Genetics submits supplemental license application for Adcetris

* Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

02 Nov 2017

BRIEF-Seattle Genetics reports Q3 earnings $0.34/shr

* Seattle Genetics reports third quarter 2017 financial results

27 Oct 2017

BRIEF-Seattle Genetics ‍announces additional clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer​

* Says ‍announces additional clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer​

11 Oct 2017

BRIEF-Astellas and Seattle Genetics initiate trial of enfortumab vedotin for ureter cancer patients

* Astellas and Seattle Genetics initiate pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer

10 Oct 2017

BRIEF-Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin

* Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer

10 Oct 2017

BRIEF-Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin

* Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer

10 Oct 2017

BRIEF-Genmab and Seattle Genetics to start study of Tisotumab Vedotin in cervical cancer

* GENMAB AND SEATTLE GENETICS TO INITIATE NEW STUDY OF NOVEL ANTIBODY-DRUG CONJUGATE TISOTUMAB VEDOTIN IN CERVICAL CANCER

10 Oct 2017

CORRECTED-BRIEF-Seattle Genetics receives FDA breakthrough therapy designation for lymphoma drug

* Seattle Genetics receives FDA breakthrough therapy designation for adcetris® (brentuximab vedotin) in frontline advanced hodgkin lymphoma

02 Oct 2017

Competitors

Earnings vs. Estimates